ARCHIVES

Two Phase III Ramucirumab Trials Both Deliver Improved Overall and Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 10 | October 25, 2013

Download PDF Visit The Full Archive

Related Articles

Rauscher To Become ACS VP For Research Nov. 1; Search Starts for New NCI Director

September 24, 1976

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

September 26, 2014

Conversation with The Cancer Letter: Statistician Lori Dodd Saw Research Question In the Midst of 2007 ODAC Debate Over Avastin

July 27, 2012

Study Explores Reasons Women Avoid Mammograms

February 25, 2011

Impath Buys Clinical Studies Support Services Network.

September 28, 2001

NCI R01 Payline At 22nd Percentile, Plans To Cut Large R01 Budgets By 18 Percent.

February 23, 2001